GlassScriptPhysician profile
Khai T Vu
NPI 1770548596
$17,010.25
in general payments reported to CMS, 2019-2025
71 companies · $4,614 in 2025
The $4,614 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $178 · 2021: $2,361 · 2022: $2,236 · 2023: $3,258 · 2024: $4,236 · 2025: $4,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,823 · Long Term Medical Supply Or Device Loan: $2,113 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,822.97 |
| Long Term Medical Supply Or Device Loan | $2,113.03 |
| Education | $171.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,072.75 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,783.32 | 2021-2025 | Calquence, Imfinzi, Tagrisso |
| Merck Sharp & Dohme LLC | $851.41 | 2022-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $704.20 | 2021-2025 | Opdivo, Opdualag, Eliquis |
| Pharmacyclics LLC, An Abbvie Company | $680.48 | 2022-2023 | Imbruvica, Epkinly |
| Pfizer INC. | $589.82 | 2019-2025 | |
| Amgen INC. | $572.61 | 2021-2025 | Lumakras, Nplate, Xgeva |
| Janssen Biotech, INC. | $555.26 | 2019-2025 | Darzalex, Imbruvica, Erleada |
| Gilead Sciences, INC. | $483.24 | 2022-2025 | Trodelvy |
| Eisai INC. | $474.12 | 2021-2025 | |
| Abbvie INC. | $443.88 | 2021-2025 | |
| Genentech USA, INC. | $414.31 | 2022-2025 | Polivy, Tecentriq, Itovebi |
| Daiichi Sankyo INC. | $364.64 | 2022-2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $323.16 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Celgene Corporation | $311.08 | 2022-2025 | Reblozyl, Pomalyst |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $310.49 | 2022-2025 | Fruzaqla, Alunbrig, Iclusig |
| Regeneron Healthcare Solutions, INC. | $276.54 | 2022-2025 | Libtayo |
| Lilly USA, LLC | $270.59 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $256.47 | 2022-2025 | |
| Incyte Corporation | $181.68 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $180.64 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.78 | 2022-2025 | Gilotrif |
| Beigene USA, INC. | $166.25 | 2023-2024 | Brukinsa |
| Puma Biotechnology, INC. | $166.02 | 2023-2025 | |
| Array Biopharma INC | $161.74 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Adaptive Biotechnologies Corporation | $160.39 | 2024-2025 | Clonoseq |
| Astellas Pharma US INC | $158.04 | 2022-2025 | Vyloy, Xtandi, Padcev |
| Karyopharm Therapeutics INC. | $156.93 | 2022-2025 | Xpovio |
| Pharmaessentia USA Corporation | $148.29 | 2023-2025 | Besremi |
| Springworks Therapeutics, INC. | $143.81 | 2024-2025 | Ogsiveo |
| Rigel Pharmaceuticals, INC. | $139.17 | 2022-2024 | Tavalisse, Rezlidhia |
| Blueprint Medicines Corporation | $138.60 | 2022-2024 | Ayvakit |
| Taiho Oncology, INC. | $128.99 | 2022-2025 | |
| Exelixis INC. | $127.54 | 2023-2025 | Cabometyx |
| Ironwood Pharmaceuticals, INC | $125.00 | 2023 | Linzess |
| Seagen INC. | $115.28 | 2022-2023 | Padcev |
| Adc Therapeutics America, INC. | $113.52 | 2022-2025 | |
| Emd Serono, INC. | $112.53 | 2022-2024 | Bavencio |
| Stemline Therapeutics INC. | $106.28 | 2023-2025 | Orserdu, Elzonris |
| Myriad Genetic Laboratories, INC. | $87.95 | 2021-2022 | |
| Deciphera Pharmaceuticals INC. | $81.13 | 2023-2024 | Qinlock |
| Tempus Ai, INC | $81.10 | 2024 | |
| Sobi, INC | $78.54 | 2022-2024 | |
| Immunogen, INC. | $73.17 | 2023 | Elahere |
| Alexion Pharmaceuticals, INC. | $72.45 | 2022-2025 | Ultomiris |
| Servier Pharmaceuticals LLC | $68.92 | 2022-2024 | |
| Aveo Pharmaceuticals, INC. | $56.54 | 2022-2025 | |
| Beone Medicines USA, INC. | $50.97 | 2025 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $45.83 | 2022-2025 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $44.83 | 2023-2025 | Somatuline Depot, Onivyde |
| Jazz Pharmaceuticals INC. | $43.17 | 2023-2025 | Vyxeos |
| Acrotech Biopharma INC. | $42.60 | 2023-2024 | Ryzneuta, Beleodaq |
| Coherus Oncology, INC. | $42.41 | 2025 | Loqtorzi |
| Teva Pharmaceuticals USA, INC. | $41.13 | 2020 | |
| Mirati Therapeutics, INC. | $40.09 | 2023-2024 | Krazati |
| Apellis Pharmaceuticals, INC. | $39.04 | 2025 | Empaveli |
| Immunocore Limited | $39.01 | 2024 | Kimmtrak |
| Boston Scientific Corporation | $36.09 | 2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Ge Healthcare | $35.31 | 2022 | |
| Caris Mpi, INC. | $32.43 | 2025 | Mi Cancer Seek |
| Syndax Pharmaceuticals, INC. | $30.11 | 2025 | |
| Telix Pharmaceuticals | $28.43 | 2024 | Illuccix |
| Iovance Biotherapeutics, INC. | $24.44 | 2025 | Amtagvi |
| Fennec Pharmaceuticals, INC. | $24.07 | 2025 | Fyarro |
| Foundation Medicine, INC. | $23.72 | 2023 | |
| Morphosys, US INC. | $22.26 | 2022 | |
| Kyowa Kirin, INC. | $17.84 | 2023 | Poteligeo |
| Accord Healthcare, INC. | $15.84 | 2025 | |
| Organon LLC | $14.92 | 2023 | Ontruzant |
| Lemaitre Vascular, INC. | $14.51 | 2019 | |
| Advanced Accelerator Applications | $13.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khai Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.